Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis

Fig. 1

OS depending on the presence of LM at onset or during disease curse. a At onset, LM presence seems to be a poor prognosis factor detecting an OS of 10 months when LM are present (n = 40) compared to 21 months when no liver metastases are diagnosed at the moment of stage IV NSCLC diagnosis (n = 196). b A better overall survival is achieved in stage IV NSCLC patients who never present liver involvement (n = 144) compared to those patients in whom LM are present during the course of the disease (n = 86).

Back to article page